MultiValent Raises $27M for Dual-Target Prostate Cancer Drug, June 17

MultiValent Biotherapies announced $27.425 million in Series A funding on June 16 to develop MVB-101, a new prostate cancer drug. The Los Altos, California-based startup licensed the drug from China-based Coherent Biopharma and plans to begin U.S. clinical trials in the third quarter of 2026. The funding targets a gap in cancer treatment where no FDA-approved drugs currently address two key tumor markers simultaneously.

Why a Smaller Drug Matters for Tumor Penetration

MVB-101 is a bivalent peptide-like drug conjugate, roughly 1/50th the size of traditional antibody drug conjugates (ADCs). The smaller structure should allow faster diffusion into solid tumors, a major limitation of larger antibody-based therapies. Like existing ADCs, MVB-101 uses monomethyl auristatin E (MMAE) as its cancer-killing payload, the same toxic compound found in Roche’s Polivy and the Pfizer-Takeda product Adcetris.

Targeting Two Tumor Markers Instead of One

MVB-101 targets both PSMA and folate receptor alpha, two validated cancer markers. No available prostate cancer therapy currently addresses both targets together. MultiValent Chief Scientific Officer Bruce Keyt stated the dual targeting is designed to provide better binding against heterogeneous tumor cells, which vary genetically within the same tumor. This approach tackles a core challenge in cancer treatment: tumor cells that resist single-target drugs.

Market Need and Clinical Timeline

Approximately 330,000 new prostate cancer cases are diagnosed annually in the United States, with nearly 3 million men living with the disease. Current treatments often cause erectile and urinary dysfunction. MultiValent expects to begin its Phase 1b/2a clinical trial in the third quarter of 2026. The company licensed exclusive global rights to MVB-101 outside of China from Coherent Biopharma.

Broader Shifts in Cancer Drug Design

The FDA’s recent draft guidance on Bayesian statistical methods in clinical trials signals a move toward more adaptive trial approaches. For therapeutic areas with small patient populations, such as certain cancers, this flexibility may support faster trial timelines and improve feasibility. Research also shows tumors evolve through sudden bursts of genetic changes, creating diverse cell subpopulations that resist treatment—a problem dual-targeting drugs like MVB-101 aim to solve.

Final Thoughts

MultiValent’s $27M funding and dual-target approach address a real gap in prostate cancer treatment. With no FDA-approved ADCs for this indication and a market of 330,000 annual diagnoses, MVB-101 has a clear clinical need if trials succeed.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.